Genesem Inc (217190) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Genesem Inc stock KRW 2,758, price KRW 6,410, that is 57.0% below the price, quality 28 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 2,986 KRW – 10,975 KRW · fair‑value band 1,931 KRW – 3,586 KRW · the 6,410 KRW price screens above the 2,758 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Genesem in your weekly email
Every Wednesday you see whether Genesem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genesem Inc. develops, manufactures, and supplies automated equipment for the semiconductor back-end process in South Korea and internationally.
Show moreShow less
It offers saw singulation, EMI shield equipment, laser marking/cutting, pick and place products, test handlers, flip chip smart factory equipment, wafer level PKG equipment, trim/form/singulation solutions, and PCB substrate equipment.
The company was founded in 2000 and is headquartered in Incheon, South Korea.
Stock analysis
Genesem Inc (217190) currently trades at 6,410 KRW, while our model-based Fair Value estimate is 2,758 KRW, 57% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 1,872 KRW per share, and 1 of the 16 models we run sit above the 6,410 KRW price.
Bear case: the Dividend Discount group reads lowest at 473.64 KRW, and 15 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 1,931 KRW (bear) to 3,586 KRW (bull), the price of 6,410 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Technology sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Genesem Inc reported revenue of 56.8B KRW in FY2025 versus 59.7B KRW in FY2021, a compound −1.3%/yr. Reported net income was 935M KRW in FY2025, compounding −35.0%/yr from FY2021.
Key figures
Market cap 84.6B KRW (≈ $62.5M) Micro · P/E ratio 569.5 · P/S ratio 1.37 · EPS (TTM) 14.29 KRW · Dividend yield 0.8% · Net margin 0.3% · Return on equity 0.4% · Return on assets (EBIT) 6.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 53% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Technology peers we cover trades at −7% fair-value upside, at −57%, 217190 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (418.72 KRW to 22,028 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear1,931 KRWFair Value 2,758 KRWBull3,586 KRW
Price 6,410 KRW · Downside -57.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income2,017 KRW2,135 KRW2,324 KRW76
EPV1,518 KRW1,567 KRW1,605 KRW74
ROIC Compounder1,518 KRW1,567 KRW1,605 KRW72
All 16 models by family
Earnings-Based
Graham-Dodd483.41 KRW1,410 KRW1,862 KRW65
Lynch FV293.10 KRW418.72 KRW544.33 KRW61
PEG = 1.0293.10 KRW418.72 KRW544.33 KRW57
EPV1,518 KRW1,567 KRW1,605 KRW74
Dividend Discount
Gordon GGM315.11 KRW498.75 KRW621.60 KRW69
DDM Multi-Stage315.11 KRW448.52 KRW538.92 KRW67
Multiples
P/E Multiple1,493 KRW1,991 KRW2,488 KRW63
P/S Multiple906.39 KRW1,209 KRW1,511 KRW58
P/B Multiple16,521 KRW22,028 KRW27,534 KRW55
EV/EBIT1,284 KRW1,753 KRW2,223 KRW66
EV/EBITDA2,156 KRW2,916 KRW3,676 KRW67
EV/Revenue587.34 KRW892.53 KRW1,198 KRW53
Asset-Based
NCAV (Graham)458.03 KRW693.99 KRW867.49 KRW54
Economic Profit
Residual Income2,017 KRW2,135 KRW2,324 KRW76
ROIC Compounder1,518 KRW1,567 KRW1,605 KRW72
Growth Earnings
Growth-Adj P/E1,178 KRW1,683 KRW2,188 KRW67
The fair value above starts from this blend and is adjusted for a cyclical trough year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−17.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Start year 2020 (pandemic). Over 10 years: +5.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−31.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.8%
Dividend (yield on the price)0.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−3% → 2%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Semiconductors · 369 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−55.4% · Below median
Profitability
Return on equity (12 months)0.4% · Below median
Return on assets1.1% · Below median
Net margin (12 months)0.3% · Below median
Operating margin (12 months)17.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)25.4% · Above median
Dividend yield (12 months)0.8% · Below median
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Semiconductors median · lower = cheaper
P/E (12 months)569.5× · Priciest 25%
P/B1.62× · Cheapest 25%
P/S (12 months)1.37× · Cheapest 25%
EV/EBITDA26.0× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 100
PAST (return on equity)2· sector 28
HEALTH (low debt)98· sector 96
DIVIDEND (yield)16· sector 21
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Genesem Inc Fair Value". https://www.fairvalue-calculator.com/stock/217190
Frequently asked questions
Is Genesem Inc (217190) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 2,758 KRW versus a price of 6,410 KRW, about 57% lower (overvalued).
What is the fair value of 217190?
Our model-based fair value for Genesem Inc is 2,758 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 6,410 KRW.
What is the quality score of 217190?
Genesem Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genesem Inc (217190)?
Our model-based price target is the fair value of 2,758 KRW (as of Nov 7, 2026) from 16 valuation models. Cautious scenario 1,931 KRW, optimistic scenario 3,586 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Genesem Inc stock forecast for 2026?
Our models put fair value at 2,758 KRW, about 57% lower versus a price of 6,410 KRW (overvalued). Cautious scenario 1,931 KRW, optimistic scenario 3,586 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genesem Inc (217190)?
Genesem Inc reported trailing-twelve-month revenue of about 59.8B KRW (latest available figure, as of Nov 7, 2026).
Does Genesem Inc pay a dividend?
Genesem Inc currently shows a dividend yield of 0.78% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Genesem Inc (217190) and when is the ex-dividend date?
Genesem Inc pays a dividend of 50.00 KRW per share a year, a dividend yield of 0.8%. The last ex-dividend date was Dec 29, 2025. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Genesem Inc (217190)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genesem Inc it is 2,758 KRW per share (as of Nov 7, 2026), against a price of 6,410 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Genesem Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 217190 trades above its calculated fair value: price 6,410 KRW, fair value 2,758 KRW, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 217190?
No. The price is what the market pays today (6,410 KRW); the fair value is what the company's own numbers justify (2,758 KRW). For Genesem Inc the two are 3,652 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genesem Inc worth?
The market values Genesem Inc at about 84.6B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 6,410 KRW; our models calculate a fair value of 2,758 KRW per share.
What do the bullish and bearish scenarios say about 217190?
Our models span a range for Genesem Inc: cautious scenario 1,931 KRW, base 2,758 KRW, optimistic 3,586 KRW per share (as of Nov 7, 2026, price 6,410 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genesem Inc (217190)?
Balance-sheet figures for Genesem Inc (as of Nov 7, 2026): return on equity 0.4%, debt of 0.04 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is 217190 from its 52-week high?
Genesem Inc trades at 6,410 KRW, about 36% below its 52-week high of 10,060 KRW and 53% above the low of 4,200 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2,758 KRW is for.
Which stocks are comparable to Genesem Inc?
From the same area (Technology) we also value NVIDIA Corporation, Taiwan Semiconductor Manufacturing Company, Broadcom Inc, Micron Technology, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genesem Inc stock attractive at the current price?
The data as of Nov 7, 2026: price 6,410 KRW, calculated fair value 2,758 KRW (−57%), Quality Score 28/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 217190 calculated?
We run Genesem Inc through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,758 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Genesem Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genesem Inc (217190)?
The closing price on Nov 9, 2026 was 6,410 KRW. Our model-based fair value is 2,758 KRW, about 57% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genesem Inc right now?
The price sits above even our optimistic bull case (3,586 KRW). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (1,931 KRW to 3,586 KRW) leaves room in how you read the outcome.
Key figures of Genesem Inc
How large is the market capitalisation of Genesem Inc (217190)?
The market capitalisation of Genesem Inc is 84.6B KRW (≈ $62.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Genesem Inc (217190)?
The price-to-earnings ratio of Genesem Inc is 569.5 (as of Oct 28, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Genesem Inc (217190)?
The price-to-sales ratio of Genesem Inc is 1.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genesem Inc (217190)?
Earnings per share at Genesem Inc are 14.29 KRW (price ÷ EPS = P/E 569.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genesem Inc (217190)?
The dividend yield of Genesem Inc is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genesem Inc (217190)?
The net margin of Genesem Inc is 0.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genesem Inc (217190)?
The return on equity (ROE) of Genesem Inc is 0.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genesem Inc (217190)?
On an EBIT basis the return on assets of Genesem Inc is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genesem Inc (217190)?
The operating margin of Genesem Inc is 17.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genesem Inc (217190)?
Revenue at Genesem Inc is growing +25.4% versus a year earlier (3y avg −1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genesem Inc (217190)?
Earnings per share at Genesem Inc are growing −21.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Genesem Inc (217190) generate?
The free cash flow of Genesem Inc is −4.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genesem Inc (217190) carry?
The net debt of Genesem Inc is 1.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genesem Inc in the live analysis
One click puts Genesem Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026